No Data
No Data
CR Double-Crane Pharma Gets Approval for Two Supplementary Drug Applications
China Resources Double-Crane Pharmaceutical (600062.SH): A sodium chloride injection with fructose has passed the consistency evaluation.
China Resources Double-Crane Pharmaceutical (600062.SH) announced that recently, the company's wholly-owned subsidiary Anhui Double-Crane Pharmaceutical Co., Ltd...
Express News | China Resources Double-Crane Pharmaceutical: Subsidiary products passed the consistency evaluation of generic drugs.
Express News | DeepSeek released the Prover-V2 model, with a parameter count reaching 671 billion.
China Resources Double-Crane Pharmaceutical (600062): The demand for infusions has slightly decreased, while non-infusion sales are steadily growing.
The company announced that in Q1 2025, it achieved revenue of 3.079 billion yuan (yoy -2.10%) and a net income of 0.507 billion yuan (yoy -1.26%); revenue/profit saw a slight decline, mainly due to the large infusion Sector.
Double-Crane Pharmaceutical's Q1 Profit Increases